Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Flecainide price, strengths & recalls

Pharmacies pay $3.22 for 30 tablets of Flecainide 50 mg tablet this week, and from $3.22 to $8.42 across its 3 priced strengths and forms. 13 manufacturers make it. It has 2 recalls on record, none ongoing. Its official label last changed on December 6, 2024.

Generic
Pharmacies pay$3.22for 30 tablets of 50 mg tablet-0.9% in 4 weeks
Fair cash price
$14.20
Strengths
3
Makers
13
Updated
Nov 11

Flecainide price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
50 mg tablet$0.1074$3.22 / 30 tablets-0.9%-4.1%
100 mg tablet$0.1739$5.22 / 30 tablets+1.6%-4.8%
150 mg tablet$0.2808$8.42 / 30 tablets+4.4%-5.4%

The lowest cost per tablet is 50 mg tablet at $0.1074. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recalls2 recalls on record, latest Jan 29, 2014

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for flecainide? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedDecember 6, 2024
Version11 of 9
EffectiveDec 4, 2024
Read the label

Flecainide Acetate Tablets, USP

This drug has a boxed warning

Mortality

Flecainide acetate was included in the National Heart Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years previously. An excessive mortality or non-fatal cardiac arrest rate was seen in patients treated with flecainide acetate compared with that seen in patients assigned to a carefully matched placebo-treated group. This rate was 16/315 (5.1%) for flecainide acetate and 7/309 (2.3%) for the matched placebo. The average duration of treatment with flecainide acetate in this study was ten months.

The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain, but at present, it is prudent to consider the risks of Class IC agents (including flecainide acetate), coupled with the lack of any evidence of improved survival, generally unacceptable in patients without life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs.

Ventricular Pro-arrhythmic Effects in Patients with Atrial Fibrillation/Flutter

A review of the world literature revealed reports of 568 patients treated with oral flecainide acetate for paroxysmal atrial fibrillation/flutter (PAF). Ventricular tachycardia was experienced in 0.4% (2/568) of these patients. Of 19 patients in the literature with chronic atrial fibrillation (CAF), 10.5% (2) experienced VT or VF. FLECAINIDE IS NOT RECOMMENDED FOR USE IN PATIENTS WITH CHRONIC ATRIAL FIBRILLATION. Case reports of ventricular proarrhythmic effects in patients treated with flecainide for atrial fibrillation/flutter have included increased PVCs, VT, ventricular fibrillation (VF), and death.

As with other Class I agents, patients treated with flecainide acetate for atrial flutter have been reported with 1:1 atrioventricular conduction due to slowing the atrial rate. A paradoxical increase in the ventricular rate also may occur in patients with atrial fibrillation who receive flecainide acetate. Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication.

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Generic makers
7 approved generic applications on the market

Flecainide questions

How much does flecainide cost without insurance?

Pharmacies pay about $3.22 for 30 tablets of flecainide 50 mg tablet ($0.1074 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $14.20. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is flecainide in shortage?

No shortage is reported for flecainide right now. We check the national shortage list every day.

Has flecainide been recalled?

2 recalls on record, none ongoing. Recalls name specific lots - check yours.

When did the flecainide label last change?

The official label was last updated on December 6, 2024 (version 11). See what changed.

Talk about flecainide

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.